Literature DB >> 22911653

Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal change PBC"?

Fahad M Khan1, Arathi Rajendra Komarla, Paulo G Mendoza, Henry C Bodenheimer, Neil D Theise.   

Abstract

UNLABELLED: Liver biopsy is important for diagnosing primary biliary cirrhosis (PBC). Prior investigations suggest that immunostaining for biliary keratin 19 (K19) may show the earliest changes suspicious for PBC, namely, loss of the canals of Hering (CoH). We aimed to study the clinical outcomes of patients whose biopsy specimens appeared histologically near normal or with minimal inflammatory changes, but in which K19 staining revealed widespread periportal CoH loss, a finding we termed "minimal change PBC." Ten patients were identified prospectively as having nearly normal or mildly inflamed biopsy specimens without diagnostic or suggestive histologic features of PBC, but with near complete CoH loss; six had available follow-up clinical data, one had follow-up biopsy. Controls for clinical and/or K19 analysis included six normal livers and biopsy specimens from 10 patients with confirmed early PBC, 10 with early stage chronic hepatitis C (CHC), and nine with resolving, self-limited hepatitis (RSLH). Staining for K19 in normal controls, livers with "minimal change" PBC, CHC, and RSLH showed 9.2 ± 6.0, 0.44 ± 0.37 (P < 0.0001), 5.7 ± 4.6 (n.s.), 4.1 ± 2.1 (P < 0.02) CoH per portal tract, respectively. Patients with available clinical follow up, compared to patients with diagnostic early-stage PBC biopsies, showed identical treatment responses to ursodeoxycholic acid, similar rates and types of nonhepatic autoimmune diseases, and/or subsequent development of autoimmune hepatitis overlap syndrome.
CONCLUSION: We suggest that CoH loss demonstrated by K19 immunostaining is an early feature in PBC. Clinical findings in the years following biopsy, including response to ursodeoxycholic acid, show identical changes to patients with biopsy confirmed PBC. We suggest that this "minimal change" feature may support a clinical diagnosis of PBC even in the absence of characteristic, granulomatous, duct destructive lesions.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22911653     DOI: 10.1002/hep.26020

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 2.  The diversity and plasticity of adult hepatic progenitor cells and their niche.

Authors:  Jiamei Chen; Long Chen; Mark A Zern; Neil D Theise; Ann Mae Diehl; Ping Liu; Yuyou Duan
Journal:  Liver Int       Date:  2017-02-23       Impact factor: 5.828

3.  Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.

Authors:  Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

4.  Keratin 19 and mesenchymal markers for evaluation of epithelial-mesenchymal transition and stem cell niche components in primary biliary cholangitis by sequential elution-stripping multiplex immunohistochemistry.

Authors:  John David Paulsen; Briana Zeck; Katherine Sun; Camila Simoes; Neil D Theise; Luis Chiriboga
Journal:  J Histotechnol       Date:  2020-10-01       Impact factor: 0.714

5.  H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4α+ Periportal Hepatocytes but Not Cytokeratin 19+ Cholangiocytes in Cholestatic Livers.

Authors:  YanChao Jiang; Yi Huang; ShiYing Cai; YongFeng Song; James L Boyer; KeZhong Zhang; Ling Gao; JiaJun Zhao; WenDong Huang; Guang Liang; Suthat Liangpunsakul; Li Wang
Journal:  Hepatol Commun       Date:  2018-09-24

Review 6.  Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.

Authors:  Samantha Sarcognato; Diana Sacchi; Federica Grillo; Nora Cazzagon; Luca Fabris; Massimiliano Cadamuro; Ivana Cataldo; Claudia Covelli; Alessandra Mangia; Maria Guido
Journal:  Pathologica       Date:  2021-06

7.  Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona.

Authors:  Susanna Tan; Napatkamon Ayutyanont; Bikash Bhattarai; Zohreh Movahedi; Lakshmi Jayaram; Robert Gish; Abdul Nadir
Journal:  BMJ Open Gastroenterol       Date:  2017-09-25

8.  Serum keratin 19 (CYFRA21-1) links ductular reaction with portal hypertension and outcome of various advanced liver diseases.

Authors:  Karim Hamesch; Nurdan Guldiken; Mahmoud Aly; Norbert Hüser; Daniel Hartmann; Pierre Rufat; Marianne Ziol; Katharina Remih; Georg Lurje; Bernhard Scheiner; Christian Trautwein; Mattias Mandorfer; Thomas Reiberger; Sebastian Mueller; Tony Bruns; Pierre Nahon; Pavel Strnad
Journal:  BMC Med       Date:  2020-11-12       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.